IGF-1 LR3

Overview

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a laboratory-made analog of the body's own insulin-like growth factor 1. It is built by adding a 13-amino-acid extension to one end of the IGF-1 molecule and substituting arginine at the third position. These two changes sharply reduce how tightly it binds IGF-binding proteins (IGFBPs), so more of the compound stays free and biologically active, and it remains in circulation far longer than ordinary IGF-1. In muscle and cell research it is used to switch on the IGF-1 receptor, which drives the same growth pathways the body normally uses to build and repair muscle.

Evidence Quality

The underlying biology is well characterized, but the human evidence for using IGF-1 LR3 to build muscle is essentially absent. Laboratory and animal studies clearly show that IGF-1 signaling increases muscle protein synthesis and activates muscle stem (satellite) cells. However, there are no controlled human trials of IGF-1 LR3 for physique or performance, and no published human pharmacokinetic or long-term safety data. Everything about real-world dosing, cycling, and results comes from bodybuilding forums and personal anecdote, which is why its practical evidence grade is low.

What the Research Shows

At the receptor level, IGF-1 LR3 binds and activates the IGF-1 receptor, triggering the PI3K/Akt/mTOR cascade that ramps up protein synthesis while suppressing the FOXO-driven breakdown pathways. It also promotes the proliferation and differentiation of satellite cells that fuse into muscle fibers. Because it largely escapes IGFBP capture, a given amount reaches receptors that native IGF-1 cannot, making it roughly 1.5 to 3 times more potent in animal models. The same pathway that grows muscle, however, also promotes cell division and blocks programmed cell death in other tissues, which is the basis of the safety concerns below.

Dosage Notes

IGF-1 LR3 is extremely potent and is measured in micrograms, not milligrams. Community protocols typically use about 20 to 50 mcg per day, with cautious beginners starting near 20 mcg and some advanced users going up to 100 mcg split across injection sites. It is almost always sold as a 1 mg (1,000 mcg) vial, because a single milligram already contains dozens of doses. Reconstituting a 1 mg vial with 1 mL of bacteriostatic water yields 1,000 mcg/mL, so on a U-100 insulin syringe each unit holds 10 mcg: 20 mcg is 2 units, 40 mcg is 4 units, and 50 mcg is 5 units. Users generally inject once daily, often after training, and run short blocks (commonly around four weeks) out of concern that continuous exposure downregulates the IGF-1 receptor.

Who Should Be Cautious

Two risks stand out. First, hypoglycemia: IGF-1 LR3 can lower blood sugar by activating IGF-1 and, at higher concentrations, insulin receptors. The approved recombinant IGF-1 drug mecasermin carries a boxed warning for low blood sugar and instructs patients to eat around the time of each dose, so injecting IGF-1 LR3 on an empty stomach or before bed is especially risky. Second, the mitogenic and cancer concern: because IGF-1 stimulates cell growth and blocks apoptosis, and because higher circulating IGF-1 is epidemiologically linked to increased risk of prostate and other cancers, IGF-1 LR3 could in theory accelerate the growth of existing or undetected tumors. Anyone with a personal or family history of cancer, active tumors, diabetes, or proliferative retinopathy should treat this compound as high-risk and avoid it.

Availability

IGF-1 LR3 is not an approved medication for muscle building. It is sold by research-chemical vendors labeled 'for research use only, not for human consumption,' and it is prohibited by the World Anti-Doping Agency both in and out of competition. Vendor listings can be confusing: a product shown as '10 mg (1 mg)' or '1 mg, 10-vial box (10 mg total)' is a kit of ten 1 mg vials, not a single 10 mg vial.

Bottom Line

IGF-1 LR3 is a long-acting, IGFBP-resistant form of IGF-1 with a well-understood muscle-growth mechanism but no human efficacy or safety evidence for that use. It is potent, microgram-dosed, and carries a genuine hypoglycemia risk plus a real theoretical cancer concern rooted in IGF-1's growth-promoting biology. It is best regarded as an experimental research chemical rather than a proven or safe physique aid.